Aligos Therapeutics, Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
Aligos Therapeutics, Inc. (ALGS) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of $5.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-03-05
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2021-12-31 was -$744.00K.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2021-09-30 was -$2.00K, a 115.38% decline year-over-year.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2021-06-30 was $2.00K, a 98.55% decline year-over-year.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2021-03-31 was $2.00K.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was $5.00K, a 95.15% decline from fiscal 2024.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was $103.00K.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was -$48.00K.
- Aligos Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2022 was -$6.00K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month as first filed | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month as first filed | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $5.00K 10-K · filed 2026-03-05 | ||||||
| 2024-12-31 | $103.00K 10-K · filed 2026-03-05 | ||||||
| 2023-12-31 | -$48.00K 10-K · filed 2025-03-10 | ||||||
| 2022-12-31 | -$6.00K 10-K · filed 2024-03-12 | ||||||
| 2021-12-31 | -$744.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$746.00K derived: sum of 2 quarters · filed 2023-03-09 | -$744.00K derived: sum of 3 quarters · filed 2023-03-09 | -$749.00K 10-K · filed 2023-03-09 | $749.00K 10-K · filed 2022-03-10 | ||
| 2021-09-30 | -$2.00K 10-Q · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | -$5.00K 10-Q · filed 2022-11-02 | -$124.00K derived: sum of 4 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $2.00K 10-Q · filed 2022-08-04 | -$2.00K 10-Q · filed 2021-08-05 | $3.00K 10-Q · filed 2022-08-04 | -$3.00K 10-Q · filed 2021-08-05 | -$122.00K derived: sum of 3 quarters · filed 2022-08-04 | -$109.00K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-04 | -$2.00K 10-Q · filed 2021-05-10 | -$124.00K derived: sum of 2 quarters · filed 2022-05-04 | -$111.00K derived: sum of 3 quarters · filed 2022-05-04 | $27.00K derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2020-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$113.00K derived: sum of 2 quarters · filed 2022-03-10 | $25.00K derived: sum of 3 quarters · filed 2022-03-10 | -$141.00K 10-K · filed 2022-03-10 | $141.00K 10-K · filed 2021-03-23 | ||
| 2020-09-30 | $13.00K 10-Q · filed 2021-11-04 | $151.00K derived: sum of 2 quarters · filed 2021-11-04 | -$15.00K 10-Q · filed 2021-11-04 | $18.00K derived: sum of 4 quarters · filed 2021-11-04 | |||
| 2020-06-30 | $138.00K 10-Q · filed 2021-08-05 | -$27.00K 10-Q · filed 2021-08-05 | $5.00K derived: sum of 3 quarters · filed 2021-08-05 | $43.00K derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | -$166.00K 10-Q · filed 2021-05-10 | -$133.00K derived: sum of 2 quarters · filed 2021-05-10 | -$95.00K derived: sum of 3 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $71.00K derived: sum of 2 quarters · filed 2021-03-23 | $118.00K 10-K · filed 2021-03-23 | ||||
| 2019-09-30 | $38.00K 10-Q · filed 2020-11-25 | $85.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |